Related Experiment Video
Updated: Dec 12, 2025
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Effect of Ezetimibe + Pitavastatin on Cardiovascular Outcomes in Patients with ST-Segment Elevation Myocardial
Hisao Otsuki1, Hiroyuki Arashi1, Junichi Yamaguchi1
1Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University, Tokyo, Japan.
Insights
Intensive lipid-lowering therapy with pitavastatin and ezetimibe significantly reduced cardiovascular events in ST-segment elevation myocardial infarction (STEMI) patients. Adding ezetimibe to statin therapy offers benefits for STEMI patients with dyslipidemia.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardiovascular events remain a concern for patients with ST-segment elevation myocardial infarction (STEMI).
- Lipid-lowering therapy is crucial for reducing cardiovascular event rates in STEMI patients.
- Dyslipidemia is a common comorbidity in STEMI patients, necessitating effective management.
Purpose of the Study:
- To evaluate the effect of intensive lipid-lowering therapy, combining pitavastatin and ezetimibe, on cardiovascular outcomes in STEMI patients.
- To compare the efficacy of pitavastatin/ezetimibe combination therapy versus pitavastatin monotherapy in reducing major adverse cardiovascular events.
Main Methods:
- A post hoc subanalysis of the HIJ-PROPER study involving 880 patients with dyslipidemia and STEMI.
- Patients were divided into two groups: intensive lipid-lowering therapy (pitavastatin + ezetimibe) and standard lipid-lowering therapy (pitavastatin monotherapy).
- The primary endpoint was a composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke, unstable angina, and ischemia-driven revascularization, assessed over a median 3.4-year follow-up.
Main Results:
- The intensive lipid-lowering therapy group showed a significantly lower cumulative rate of the primary endpoint (31.9%) compared to the standard therapy group (39.7%) (HR, 0.77; p = 0.02).
- Significantly lower rates of all-cause death (HR, 0.45; p = 0.01) and nonfatal stroke (HR, 0.77; p = 0.02) were observed in the intensive therapy group.
- The combination of pitavastatin and ezetimibe demonstrated a reduction in cardiovascular events in STEMI patients compared to pitavastatin monotherapy.
Conclusions:
- Adding ezetimibe to pitavastatin therapy may be beneficial for managing dyslipidemia in patients with STEMI.
- Intensive lipid-lowering therapy with pitavastatin and ezetimibe can improve clinical outcomes in STEMI patients.
- This strategy warrants consideration for optimizing cardiovascular risk reduction in this patient population.
Abstract:
Lipid-lowering therapy is necessary to reduce cardiovascular event rates in patients with ST-segment elevation myocardial infarction (STEMI). This study aimed to evaluate the effect of intensive lipid-lowering therapy, which comprised pitavastatin and ezetimibe, on patients with STEMI. We therefore undertook a post hoc subanalysis of the HIJ-PROPER study's data that examined the clinical outcomes of the patients with dyslipidemia and STEMI (n = 880) who received pitavastatin and ezetimibe therapy (intensive lipid-lowering therapy group) or pitavastatin monotherapy (standard lipid-lowering therapy group), and we evaluated their cardiovascular events. The primary end point was a composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke, unstable angina, and ischemia-driven revascularization. During the median 3.4-year follow-up period, the cumulative rates of the primary end point were 31.9% and 39.7% in the intensive lipid-lowering therapy and standard lipid-lowering therapy groups, respectively (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.62 to 0.97; p = 0.02). Compared with the standard lipid-lowering therapy group, the intensive lipid-lowering therapy group had significantly lower all-cause death (6.9% vs 3.2%; HR, 0.45; 95% CI, 0.23 to 1.84; p = 0.01) and nonfatal stroke (2.9% vs 1.6%; HR, 0.77; 95% CI, 0.62 to 0.97; p = 0.02) rates. Patients with pitavastatin and ezetimibe therapy, as compared with pitavastatin monotherapy, had a lower cardiovascular event in STEMI patients. In conclusion, adding ezetimibe to statin therapy may be beneficial for patients with dyslipidemia and STEMI.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:26Coronary Artery Disease IV: Preventive Measures
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...